

Ref: SEC/SE/2024-25 Date: January 3, 2025

To,
Corporate Relations Department
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai- 400001

BSE Scrip Code: 500096

Listing Department

National Stock Exchange of India Ltd.

Exchange Plaza, 5th Floor

Plot No. C/1, G Block, Bandra Kurla Complex

Bandra (E), Mumbai – 400051

NSE Scrip Symbol: DABUR

Sub: Quarterly Update - Q3 FY2024-25

Dear Sir/Madam,

Please find enclosed an update on the performance and demand trends witnessed during the quarter ended December 31, 2024 (Q3 FY25).

This will be followed by detailed financial results and earnings presentation once the Board of Directors of the Company approves the consolidated and standalone financial results for the quarter ended December 31, 2024.

Thanking you,

Yo<mark>urs faithfully</mark> For **Dabur India Limited**

(Saket Gupta)

Company Secretary and Compliance Officer

Encl: as above



Update for Quarter ended December 31, 2024 (Q3 FY25)

This update provides an overall summary of the performance and demand trends witnessed during the quarter ended December 31, 2024 (Q3 FY25). This will be followed by detailed financial results and earnings presentation once the Board of Directors of the Company approves the consolidated and standalone financial results for the quarter ended December 31, 2024.

During Q3, rural consumption for FMCG was resilient and continued to grow faster than urban. While general trade was still under pressure, alternative channels like modern trade, e-commerce, and quick commerce continued to post strong growth.

Dabur's consolidated revenue is expected to register low single digit growth during Q3 FY25.

In India business, HPC is expected to grow in mid to high single digits, while Health Care is expected to be flattish due to the delayed winter onset. While Beverages portfolio is expected to report muted performance, our culinary business under the brand 'Hommade' and 'Badshah' continued to perform well during Q3 and is expected to post strong double-digit growth.

The International Business is expected to register double-digit growth in constant currency terms, led by good momentum in MENA region, Egypt, Bangladesh and US business.

In Q3, inflationary pressures were witnessed in some segments which were partially mitigated through tactical price increases and cost-efficiency initiatives. We anticipate flattish operating profit growth in Q3.

With improving macroeconomic indicators, we expect FMCG growth to revive and sequential improvement in demand going forward. We remain committed to delivering superior performance across all business segments and enhancing market share within our portfolio. Our strategic priorities continue to centre on brand building, sustained profitable growth, and long-term value creation.

Inalamba.

About Dabur India Ltd

Dabur India Limited is one of India's leading FMCG Companies. Building on a legacy of quality and experience for 140 years, Dabur is today India's most trusted name and one of the world's largest Ayurvedic and Natural Health Care Company. Dabur India's FMCG portfolio today includes nine distinct Power Brands: Dabur Chyawanprash, Dabur Honey, Dabur Honitus, Dabur PudinHara and Dabur Lal Tail in the Healthcare space; Dabur Amla, Dabur Red Paste and Vatika in the Personal Care category; and Real in the Foods space. During FY 2023-24, Dabur recorded consolidated revenue from operations of INR 12,404 crore and consolidated profit after tax of INR 1,843 crore.

For further information please contact:

Isha Lamba

Email: isha.lamba@dabur.com

Ayush Goyal

Email: ayush.goyal@dabur.com

Disclaimer:

The statements and financials disclosed above may differ from the reported financials to reflect the real business financial performance. Some of the statements in this communication may be forward looking statements within the meaning of applicable laws and regulations. Actual results might differ substantially from those expressed or implied.

Thalamba.